APELLIS PHARMACEUTICALS INC (APLS)       46.88  -2.5 (-5.06%)

46.88  -2.5 (-5.06%)

US03753U1060 - Common Stock - After market: 46.88 0 (0%)

APELLIS PHARMACEUTICALS INC46.88

NASDAQ:APLS (12/6/2022, 7:21:42 PM)-2.5 (-5.06%)

After market: 46.88 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-07 2022-11-07/amc Earnings (Next) 02-27 2023-02-27
Ins Owners 14.2% Inst Owners 87.78%
Market Cap 5.18B Shares 110.58M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 81.67
IPO 11-09 2017-11-09

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

APLS Daily chart

Company Profile

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic and complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company is headquartered in Waltham, Massachusetts and currently employs 476 full-time employees. The company went IPO on 2017-11-09. The firm is developing pegcetacoplan with Sobi for systemic administration in several indications, including paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, cold agglutinin disease, and hematopoietic stem cell transplantation thrombotic microangiopathy. The firm's advanced clinical programs targeting component 3 with Phase III clinical trials of its lead product candidate, pegcetacoplan, in multiple indications. Pegcetacoplan is a conjugate of a compstatin analogue, formulated both for ophthalmological administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin.

Company Info

APELLIS PHARMACEUTICALS INC

100 Fifth Avenue

Waltham MASSACHUSETTS 02451

P: 16179775700.0

CEO: Cedric Francois

Employees: 476

Website: https://apellis.com/

APLS News

News Image14 days ago - Apellis Pharmaceuticals, Inc.Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) --  Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in...

News Image14 days ago - Apellis Pharmaceuticals, Inc.Apellis Pharmaceuticals to Present at Upcoming Investor ConferencesNews Image19 days ago - Investor's Business DailyApellis Pharmaceuticals Surges On New Review Date For Eye-Disease Treatment

The delay is at Apellis' behest. The company wanted to include updated data in its request.

News Image19 days ago - Seeking AlphaApellis stock rises 17% as FDA accepts to review new data for eye drug

Apellis Pharmaceuticals (APLS) said the U.S. Food and Drug Administration (FDA) accepted the company's additional data filed for an application seeking approval...

News Image19 days ago - Apellis Pharmaceuticals, Inc.Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)

WALTHAM, Mass., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in...

News Image19 days ago - Apellis Pharmaceuticals, Inc.Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)

APLS Twits

Here you can normally see the latest stock twits on APLS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example